Sophie Rochon

National Director, Health Policy, Patient Access and Patient Support Programs

Novartis Oncology

Dynamic, versatile and accomplished negotiator, Sophie is recognized for her leadership and problem solving skills. Graduate and postgraduate studies in health economics are combined with her experience in market access strategies, pricing and negotiation, stakeholder management and health policy. She is currently the national director of health policy,  patient access and patient support programs at Novartis Oncology where she is also responsible for health system partnerships. She is the Vice President of the Canadian Association for Healthcare Reimbursement. Sophie is active with both industry associations, Innovative Medicines Canada and BIOTECanada.

Sophie started her career in 2001 at AETMIS (now INESSS) as a health economist. She then joined Pfizer in 2002 as a manager of health economics and outcomes research. She moved on to the role of patient access manager in the field in 2006, managing reimbursement dossier for the province of Quebec before joining Janssen in 2015 as the Quebec director of government affairs and reimbursement.   She joined Novartis Oncology in 2018.


All Sessions by Sophie Rochon

Printer Friendly See Full Agenda

Agenda: Day 1 Oct 5, 2020

10:00 am

10:00 am

FIRESIDE CHAT: THE INCREASED OPPORTUNITY FOR PUBLIC / PRIVATE PARTNERSHIPS TO FIX THE SYSTEM

Using Cardiovascular Disease As An Important Example

The healthcare system in Canada has been under tremendous strain for years. The ongoing crisis has been amplified by the pandemic, which caused severe global disruption in the delivery of health care for non-communicable diseases, BUT early detection and diagnosis are critical to keeping people out of hospitals and reducing the need for procedures and surgeries.

Now is the time to take a closer look at how the public and private sectors can band together to drive solutions to crucial healthcare problems, alleviate pressure throughout the system, and drive positive and lasting change.

The issue of cardiovascular disease (CVD) is particularly pressing as it is the second leading cause of death in Canada after cancer and now providers are facing an unprecedented backlog in the need for follow-up care to prevent future heart attacks and strokes among people at elevated risk. Novartis is seeking to address care inequities, barriers to access, and challenges and opportunities, by investing and institutionalizing best-in-class provincial teams to drive partnerships at the local healthcare system level.

Agenda: Day 2 Oct 6, 2020